Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose first-in-human study of RO5459072 in healthy volunteers
NL-OMON41854Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in lupus nephritis (LN) and systemic lupus erythematosus (SLE) comparing RO5459072 with Placebo (2 arms). Primary endpoint: Safety and tolerability of RO5459072. Started Dec 2014; status: active, not recruiting.
02
Drugs
petesicatib
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON41854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41854.